AstraZeneca Plc is increasingly looking to the US for growth as its once fast-expanding China business faces challenges amid ...

AZN beats third-quarter estimates for earnings and sales. It raises its sales and profit outlook for 2024 for the second time ...

A team of researchers have applied a novel blood test that can detect early signs of potentially fatal lung damage in cancer ...

Following mixed study results, the partners have backed away from seeking broad clearance of dato-dxd in lung cancer and ...

The U.K. drugmaker also announced plans to drop another $2 billion on expanding its R&D and manufacturing footprint in the ...

(Reuters) -Drugmaker AstraZeneca lifted its annual sales and profit forecast for the second time this year on Tuesday, helped ...

AstraZeneca Plc raised its annual forecast, driven by strong demand for its blockbuster cancer drugs, and revealed a plan to ...

AZ later said that it believes Chinese authorities are looking into whether the company’s employees had illegally imported ...

The company previously said it believes Chinese authorities are probing allegations that employees illegally imported breast-cancer drug Enhertu and liver-cancer treatment Imjudo from Hong Kong, and ...

ADCs, including the widely used cancer drug Enhertu (trastuzumab deruxtecan), represent a new wave of targeted therapies.

Fiera Capital Corp trimmed its holdings in AstraZeneca PLC (NASDAQ:AZN – Free Report) by 5.9% during the third quarter, according to the company in its most recent filing with the Securities and ...

Shore Capital reiterated their buy rating on shares of AstraZeneca (LON:AZN – Free Report) in a research report report ...